City Briefs: Tissue Regenix CEO back in action; “Exciting moment” for Provident suitor NSF; Sirius fundraising oversubscribed
The CEO of listed medtech company Tissue Regenix will be back in action in June.
Steve Couldwell stepped aside in January 2019 to undergo medical treatment for an unspecified condition.
John Samuel, chairman, Tissue Regenix Group plc: "The Board and I look forward to welcoming Steve back into the full time CEO position and are grateful for his ongoing commitment.
“During his necessary absence Steve remained in daily contact with the business and continued to be integral to implementing the business strategy and establish... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...